Showing results (41-50 of 61) with videos related to
Sort By:
Pageof 7
Transplantation and Cellular Therapy|July 10, 2026
Impact of prior CAR T-cell treatment on graft-vs-host disease and non-relapse mortality after allogeneic transplantationTamer Othman, Dongyun Yang, Geoffrey Shouse, et al.Nature Medicine|December 10, 2023
Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trialLihua E Budde, Adam J Olszewski, Sarit Assouline, et al.Blood|April 21, 2026
Mosunetuzumab plus polatuzumab vedotin in relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 studyLihua E Budde, Manali Kamdar, Sarit E Assouline, et al.Blood Advances|April 17, 2023
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphomaNancy L Bartlett, Sarit Assouline, Pratyush Giri, et al.Blood Advances|October 8, 2025
Polatuzumab vedotin in CNS lymphoma: proof-of-concept study for blood-brain barrier penetrationLei Gao, Avyakta Kallam, Geoffrey Shouse, et al.Blood|April 28, 2016
Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHLXiuli Wang, Leslie L Popplewell, Jamie R Wagner, et al.Cancer Immunology Research|October 23, 2020
The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity against Both Central Nervous System and Systemic LymphomaXiuli Wang, Christian Huynh, Ryan Urak, et al.Cancer Discovery|April 7, 2024
CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell CarcinomaSumanta K Pal, Ben Tran, John B A G Haanen, et al.Blood Advances|July 24, 2025
Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysisNausheen Ahmed, Swetha Thiruvengadam, Mehdi Hamadani, et al.Nature Medicine|June 12, 2024
PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trialTanya B Dorff, M Suzette Blanchard, Lauren N Adkins, et al.Pageof 7